![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF716 |
Gene summary for ZNF716 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF716 | Gene ID | 441234 |
Gene name | zinc finger protein 716 | |
Gene Alias | ZNF716 | |
Cytomap | 7p11.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A6NP11 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
441234 | ZNF716 | HCC1 | Human | Liver | HCC | 4.24e-05 | 1.30e+00 | 0.5336 |
441234 | ZNF716 | HCC2 | Human | Liver | HCC | 2.99e-18 | 1.42e+00 | 0.5341 |
441234 | ZNF716 | HCC5 | Human | Liver | HCC | 1.46e-13 | 2.28e+00 | 0.4932 |
441234 | ZNF716 | S014 | Human | Liver | HCC | 4.18e-04 | 1.36e-01 | 0.2254 |
441234 | ZNF716 | S016 | Human | Liver | HCC | 2.55e-03 | 1.11e-01 | 0.2243 |
441234 | ZNF716 | S029 | Human | Liver | HCC | 2.42e-03 | 2.08e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF716 | SNV | Missense_Mutation | c.155T>C | p.Leu52Pro | p.L52P | A6NP11 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
ZNF716 | SNV | Missense_Mutation | c.1199N>A | p.Arg400Lys | p.R400K | A6NP11 | protein_coding | tolerated(0.4) | benign(0.041) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
ZNF716 | SNV | Missense_Mutation | c.692N>G | p.His231Arg | p.H231R | A6NP11 | protein_coding | deleterious(0.03) | benign(0.029) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD | |
ZNF716 | insertion | In_Frame_Ins | novel | c.587_588insATCTTCTCA | p.Met196delinsIleSerSerGln | p.M196delinsISSQ | A6NP11 | protein_coding | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | ||
ZNF716 | insertion | In_Frame_Ins | novel | c.587_588insATCTTCTCA | p.Met196delinsIleSerSerGln | p.M196delinsISSQ | A6NP11 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
ZNF716 | insertion | Frame_Shift_Ins | rs782748894 | c.588_589insTATCA | p.Leu197TyrfsTer6 | p.L197Yfs*6 | A6NP11 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
ZNF716 | SNV | Missense_Mutation | c.577T>C | p.Ser193Pro | p.S193P | A6NP11 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ZNF716 | SNV | Missense_Mutation | c.911C>A | p.Ala304Asp | p.A304D | A6NP11 | protein_coding | deleterious(0.01) | benign(0.056) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF716 | SNV | Missense_Mutation | novel | c.416A>C | p.Lys139Thr | p.K139T | A6NP11 | protein_coding | deleterious(0.05) | possibly_damaging(0.576) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF716 | SNV | Missense_Mutation | novel | c.1373N>G | p.His458Arg | p.H458R | A6NP11 | protein_coding | deleterious(0) | possibly_damaging(0.839) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |